EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Carrier‐Free, Amorphous Verteporfin Nanodrug for Enhanced Photodynamic Cancer Therapy and Brain Drug Delivery

John A Quinlan, Collin T Inglut, Payal Srivastava, Idrisa Rahman, Jillian Stabile, Brandon Gaitan, Carla Arnau Del Valle, Kaylin Baumiller, Anandita Gaur, Wen-An Chiou, Baktiar Karim, Nina Connolly und 4 weitere

Advanced Science · 2024-05 · 11 (17)

DOI: 10.1002/advs.202302872 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 06.03.2024. Verfasst von John A Quinlan und 15 weiteren Autor:innen. Beteiligte Einrichtung: Fischell Department of Bioengineering, University of Maryland, College Park, MD, 20742, USA. Hauptthemen laut MEDLINE: Photochemotherapy, Verteporfin, Photosensitizing Agents, Brain Neoplasms. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIBIB NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM) is hard to treat due to cellular invasion into functioning brain tissues, limited drug delivery, and evolved treatment resistance. Recurrence is nearly universal even after surgery, chemotherapy, and radiation. Photodynamic therapy (PDT) involves photosensitizer administration followed by light activation to generate reactive oxygen species at tumor sites, thereby killing cells or inducing biological changes. PDT can ablate unresectable GBM and sensitize tumors to chemotherapy. Verteporfin (VP) is a promising photosensitizer that relies on liposomal carriers for clinical use. While lipids increase VP's solubility, they also reduce intracellular photosensitizer accumulation. Here, a pure‐drug nanoformulation of VP, termed “NanoVP”, eliminating the need for lipids, excipients, or stabilizers is reported. NanoVP has a tunable size (65–150 nm) and 1500‐fold higher photosensitizer loading capacity than liposomal VP. NanoVP shows a 2‐fold increase in photosensitizer uptake and superior PDT efficacy in GBM cells compared to liposomal VP. In mouse models, NanoVP‐PDT improved tumor control and extended animal survival, outperforming liposomal VP and 5‐aminolevulinic acid (5‐ALA). Moreover, low‐dose NanoVP‐PDT can safely open the blood‐brain barrier, increasing drug accumulation in rat brains by 5.5‐fold compared to 5‐ALA. NanoVP is a new photosensitizer formulation that has the potential to facilitate PDT for the treatment of GBM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhotochemotherapyVerteporfinPhotosensitizing AgentsBrain NeoplasmsDrug Delivery SystemsAnimalsMiceGlioblastomaNanoparticlesDisease Models, AnimalHumansRatsLiposomesCell Line, TumorBrain

Stichwörter der Autor:innen

amorphous drug nanoparticlesblood‐brain barriercancerphotodynamic therapyphotosensitizers

Substanzen

VerteporfinPhotosensitizing AgentsLiposomes

Autor:innen und Institutionen

  • Fischell Department of Bioengineering, University of Maryland, College Park, MD, 20742, USA.
  • Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
  • Advanced Imaging and Microscopy Laboratory, Maryland Nano Center, University of Maryland, College Park, MD, 20742, USA.
  • Molecular Histopathology Laboratory, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, 21701, USA.
  • Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
  • Department of Neurosurgery, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.

ORCID-Profile: Huang-Chiao Huang

Förderung

  • NIBIB NIH HHS
  • NIH HHS
  • National Institutes of Health
  • National Science Foundation

Zitieren

APA

Quinlan, J. A., Inglut, C. T., Srivastava, P., Rahman, I., Stabile, J., Gaitan, B., Arnau Del Valle, C., Baumiller, K., Gaur, A., Chiou, W. A., Karim, B., Connolly, N., Robey, R. W., Woodworth, G. F., Gottesman, M. M., & Huang, H. C. (2024). Carrier‐Free, Amorphous Verteporfin Nanodrug for Enhanced Photodynamic Cancer Therapy and Brain Drug Delivery. Advanced Science, 11(17). https://doi.org/10.1002/advs.202302872

Vancouver

Quinlan JA, Inglut CT, Srivastava P, Rahman I, Stabile J, Gaitan B, et al. Carrier‐Free, Amorphous Verteporfin Nanodrug for Enhanced Photodynamic Cancer Therapy and Brain Drug Delivery. Advanced Science. 2024;11(17). doi:10.1002/advs.202302872

BibTeX
@article{Quinlan2024,
  author = {Quinlan, John A and Inglut, Collin T and Srivastava, Payal and Rahman, Idrisa and Stabile, Jillian and Gaitan, Brandon and Arnau Del Valle, Carla and Baumiller, Kaylin and Gaur, Anandita and Chiou, Wen-An and Karim, Baktiar and Connolly, Nina and Robey, Robert W and Woodworth, Graeme F and Gottesman, Michael M and Huang, Huang-Chiao},
  title = {Carrier‐Free, Amorphous Verteporfin Nanodrug for Enhanced Photodynamic Cancer Therapy and Brain Drug Delivery},
  journal = {Advanced Science},
  year = {2024},
  volume = {11},
  number = {17},
  doi = {10.1002/advs.202302872}
}
Kostenlos starten →